KCNH5 (Potassium Voltage-Gated Channel Subfamily H Member 5) encodes the voltage-gated potassium channel EAG2 (ether-à-go-go 2), also known as Kv10.2 or hERG2. This channel belongs to the EAG (ether-à-go-go) family of potassium channels and plays important roles in neuronal excitability, synaptic function, and cellular proliferation. In the context of neurodegenerative diseases, KCNH5/EAG2 is relevant for its roles in regulating neuronal firing patterns, synaptic transmission, and its expression patterns in brain regions affected by Alzheimer's disease, Parkinson's disease, and epilepsy—a common comorbidity in neurodegenerative disorders.
¶ Gene and Protein Structure
The KCNH5 gene is located on chromosome 14q23.1 and consists of 16 exons spanning approximately 20 kb of genomic DNA. It encodes a protein of 989 amino acids forming the core alpha subunit of the EAG2 potassium channel.
EAG2 contains several critical structural domains:
- N-terminal Per-Arnt-Sim (PAS) domain: Senses voltage and redox state
- Voltage sensor domain (VSD): Segments S1-S4 detect membrane potential changes
- Pore domain: Segments S5-S6 form the K+ selectivity filter
- C-terminal cyclic nucleotide-binding homology domain (cNBHD): Modulates channel activity
- Leucine zipper motif: Facilitates tetramerization
EAG2 forms functional channels as:
- Tetrameric assembly: Four alpha subunits form the pore
- Auxiliary subunits: May associate with beta subunits
- Splice variants: Multiple isoforms with distinct properties
EAG2 regulates neuronal firing in several ways:
- Repolarization: Mediates outward K+ current to reset membrane potential
- Firing pattern: Influences action potential shape and frequency
- Resting membrane potential: Contributes to baseline conductance
- Dendritic integration: Affects synaptic integration
EAG2 shows distinct expression patterns:
- Hippocampus: High expression in CA1 pyramidal neurons
- Cortex: Layer-specific expression in pyramidal neurons
- Cerebellum: Purkinje cell expression
- Thalamus: Moderate expression in relay neurons
- Substantia nigra: Expression in dopaminergic neurons
EAG2 modulates synaptic transmission:
- Presynaptic terminals: Regulates vesicle release probability
- Postsynaptic responses: Shapes excitatory/inhibitory balance
- Plasticity: Affects long-term potentiation and depression
¶ Cell Cycle and Proliferation
Outside the nervous system, EAG2 affects:
- Cell cycle progression: Controls G1/S transition
- Cellular proliferation: Aberrant expression in tumors
- Migration: Affects cell motility
KCNH5 variants have been implicated in epilepsy:
- Loss-of-function mutations: Cause epilepsy phenotypes
- Channel dysfunction: Leads to hyperexcitability
- Therapeutic targeting: EAG2 modulators as anticonvulsants
The channel's role in neuronal excitability makes it relevant for:
- Temporal lobe epilepsy
- Febrile seizures
- Absence seizures
In Alzheimer's disease, EAG2 may play several roles:
Neuronal Excitability Changes
- AD neurons show altered firing patterns
- EAG2 dysregulation contributes to network dysfunction
- Potassium channels as therapeutic targets
Amyloid Interactions
- Aβ affects neuronal potassium channel function
- EAG2 expression altered in AD brain
- Possible direct protein-protein interactions
Synaptic Dysfunction
- EAG2 modulates synaptic plasticity
- Altered in AD-relevant circuits
- Contributes to cognitive decline
In Parkinson's disease:
Basal Ganglia Circuitry
- EAG2 expressed in striatal neurons
- Modulates direct/indirect pathway activity
- Dopamine regulates channel expression
Dopaminergic Neurons
- EAG2 in substantia nigra pars compacta
- May affect neuron survival
- Potential therapeutic target
EAG2 has been studied in:
- Schizophrenia: Altered expression in prefrontal cortex
- Bipolar disorder: Channel dysfunction hypotheses
- Autism spectrum disorders: Genetic association studies
¶ Channel Gating and Modulation
EAG2 has unique gating properties:
- Activation: Slow voltage-dependent opening
- Deactivation: Rapid closure upon repolarization
- Inactivation: Minimal inactivation during sustained depolarization
Multiple factors modulate EAG2:
- Phosphorylation: PKA, PKC affect channel function
- Redox state: Oxidative stress modulates gating
- Lipids: Membrane lipid composition matters
- Temperature: Thermal sensitivity relevant for seizures
EAG2 is targeted by several compounds:
- Astemizole: H1 antagonist blocks EAG2
- Terfenadine: Histamine antagonist with EAG2 block
- Clozapine: Atypical antipsychotic affects EAG2
- Dozens of research compounds: Tool compounds available
EAG2 modulators as anticonvulsants:
- AST-001: Novel EAG2 activator
- Existing drugs: Mechanism includes EAG2 effects
- Combination therapy: Synergistic approaches
Potential therapeutic approaches:
- Channel openers: Enhance EAG2 function
- Selective modulators: Targeted compounds
- Gene therapy: Viral vector delivery
EAG2-targeting drugs must consider:
- Cardiac effects: hERG1 (KCNH2) similarity
- CNS penetration: Blood-brain barrier
- On-target toxicity: Neuronal excitability
KCNH5 variants include:
- Missense mutations: Most common pathogenic type
- Truncating mutations: Loss-of-function
- Splice variants: Aberrant processing
- Carrier frequency: Rare in population
- Founder effects: Some populations show clusters
- De novo mutations: Important in sporadic cases
Key experimental approaches:
- Patch clamp: Two-electrode, whole-cell, inside-out
- Voltage protocols: Activation, inactivation curves
- Single-channel: Gating kinetics
- cRNA injection: Xenopus oocyte expression
- CRISPR/Cas9: Genetic manipulation
- RNAi: Knockdown studies
Research models include:
- Xenopus oocytes: Expression system
- HEK293 cells: Mammalian expression
- Primary neurons: Native channel studies
- Transgenic mice: In vivo models
EAG2 interacts with other K+ channels:
- EAG1 (KCNH1): Closely related paralog
- ERG1 (KCNH2): Cardiac relevance
- Other Kv channels: Redundancy, compensation
In neurons, EAG2 coordinates with:
- Sodium channels: Action potential repolarization
- Calcium channels: Excitable coupling
- Chloride channels: Inhibitory modulation
KCNH5 testing relevant for:
- Epilepsy: Diagnostic testing available
- Family screening: At-risk relatives
- Prenatal testing: In severe cases
Clinical care considerations:
- Seizure control: Antiepileptic drug selection
- Monitoring: EEG, clinical assessment
- Multidisciplinary care: Neurology, genetics